FindTrial
Sign In

UCPVax

DRUG5 trials

Sponsors

Centre Hospitalier Universitaire de Besancon

Conditions

Anal Canal CancerCervical CancerGlioblastomaHepatocellular CarcinomaMetastatic Non-small Cell Lung CancerPrimary GlioblastomaSquamous Cell Carcinoma of the Head and Neck

Phase 1

Universal Cancer Peptide-based Vaccination in Metastatic NSCLC
CompletedNCT02818426
Centre Hospitalier Universitaire de BesanconMetastatic Non-small Cell Lung Cancer
Start: 2016-04-20End: 2024-12-31Updated: 2025-01-09

Phase 2

Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL)
CompletedNCT03946358
Centre Hospitalier Universitaire de BesanconAnal Canal Cancer, Cervical Cancer, Squamous Cell Carcinoma of the Head and Neck
Start: 2020-02-18End: 2024-11-01Updated: 2024-12-20
Anticancer Therapeutic Vaccination Using Telomerase-derived Universal Cancer Peptides in Glioblastoma
CompletedNCT04280848
Centre Hospitalier Universitaire de BesanconGlioblastoma
Start: 2020-05-26End: 2024-12-31Updated: 2025-01-09
Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
RecruitingNCT05528952
Centre Hospitalier Universitaire de BesanconHepatocellular Carcinoma
Start: 2022-09-27End: 2030-02-27Target: 105Updated: 2026-03-16
Evaluation of UCPVax Vaccine +/- Pembrolizumab Combined With Standard Treatment as Adjuvant Therapy in Patients With Unmethylated MGMT Glioblastoma
Not yet recruitingNCT07347210
Centre Hospitalier Universitaire de BesanconPrimary Glioblastoma
Start: 2026-01-01End: 2029-07-01Target: 98Updated: 2026-01-16

Related Papers

UCPVax, a CD4 helper peptide vaccine, induces polyfunctional Th1 cells, antibody response, and epitope spreading to improve antitumor immunity.
2025-06-20
A phase II study of an anti-telomerase CD4+ T-helper vaccine (UCPVax) with or without temozolomide in newly diagnosed glioblastoma.
Journal of Clinical Oncology2025-05-28
KS01.6.A UCPVAX-GLIO: A PHASE II TRIAL EVALUATING THE IMMUNOGENICITY AND EFFICACY OF AN ANTI-TELOMERASE VACCINE IN PATIENTS WITH NEWLY DIAGNOSED GBM
Neuro-Oncology2023-09-013 citations
Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82).
2023-07-2919 citations
Anti-telomerase vaccine in patients with newly diagnosed, unmethylated MGMT glioblastoma: A phase II study.
Journal of Clinical Oncology2023-06-017 citations
LBA6 UCPVax therapeutic vaccination promotes cytotoxic and Th1 polarized antitumor CD4 T cells and epitope spreading in patients with advanced non-small cell lung cancer
Immuno-Oncology Technology2022-12-01
A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 TH1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL Study
Frontiers in Oncology2022-07-1926 citations